Findings

What do systematic reviews say?

697 questions · 708 findings · 47 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 263 · 37.1%GRADE not reported 12 · 1.7%Very low 146 · 20.6%Low 168 · 23.7%Moderate 98 · 13.8%High 21 · 3%

Propionyl‐L‐carnitine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Propionyl‐L‐carnitine vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Complete closureUlcer area was determined by computerized planimetry · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes complete closureUlcer area was determined by computerized planimetry compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.4 [0.15, 1.04]
1 study · 55 participants
Very low

RGD peptide matrix vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Change in size ulcers healed ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Adverse events · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.76 [0.5, 1.17]
1 study · 55 participants
Very low

Isoxsuprine vs placebo

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Isoxsuprine vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Adverse events ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard rhGH vs placebo

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low